Moleculin Biotech (NASDAQ:MBRX) Earns Sell Rating from Analysts at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of Moleculin Biotech (NASDAQ:MBRX) in a note issued to investors on Monday. The firm set a “sell” rating on the stock.

Moleculin Biotech Price Performance

Moleculin Biotech stock opened at $2.62 on Monday. Moleculin Biotech has a 1-year low of $2.12 and a 1-year high of $15.75. The company has a fifty day simple moving average of $2.50 and a 200 day simple moving average of $3.48.

Moleculin Biotech (NASDAQ:MBRX) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($2.23) EPS for the quarter, missing analysts’ consensus estimates of ($2.10) by ($0.13). On average, equities analysts expect that Moleculin Biotech will post -8.6 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Moleculin Biotech stock. Armistice Capital LLC lifted its position in Moleculin Biotech, Inc. (NASDAQ:MBRX) by 5.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 156,000 shares of the company’s stock after buying an additional 7,505 shares during the quarter. Armistice Capital LLC owned about 6.75% of Moleculin Biotech worth $549,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 15.52% of the company’s stock.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.